Q-omics provides the consensus-scored TTPAL profile across patient tissues and cancer cell-line models. TTPAL expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TTPAL is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TTPAL RNA expression shows 21,137 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where TTPAL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTPAL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTPAL survival associations across molecular data types. TTPAL RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTPAL RNA expression–survival associations across cancer types. High TTPAL expression shows unfavorable associations in HNSC, CESC, UVM, ACC, LUSC and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TTPAL RNA expression.
This table summarizes TTPAL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TTPAL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTPAL shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LUAD, LUSC and BLCA. The HNSC box plot shows higher TTPAL RNA expression in tumor versus normal tissue (log2 FC = +1.455, t-test p < 0.001).
This table shows molecular features associated with TTPAL in patient tissues and cancer cell lines. In patient samples, TTPAL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTPAL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
